Chinese government approves pricing & reimbursement for NeoStem’s arthroscopic orthopedic autologous adult stem cell based treatment |

Chinese government approves pricing & reimbursement for NeoStem’s arthroscopic orthopedic autologous adult stem cell based treatment

Local Chinese Government Authorities Approve Pricing and Reimbursement for NeoStem’s Licensed Adult Stem Cell Treatments for Orthopedic Applications in China (Press Release)

NeoStem holds an exclusive royalty-bearing, perpetual and irrevocable license to use the Regenerative Sciences, Inc. stem cell-based orthopedic technology in Asia, and is in the early stages of implementing operations designed to offer these orthopedic treatments in China through an initial network of hospitals, of which Wendeng Hospital is the first.

Leave a Reply

Your email address will not be published. Required fields are marked *